GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

linvoseltamab   Click here for help

GtoPdb Ligand ID: 13305

Synonyms: Lynozyfic® | REGN-5458 | REGN5458
Approved drug
linvoseltamab is an approved drug
Compound class: Antibody
Comment: Linvoseltamab (REGN5458) is an investigational bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) and CD3e [1]. It simultaneously engages BCMA on B cells and CD3e on CD4+ and CD8+ T cells to induce T cell-mediated killing of BCMA+ve myeloma cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Linvoseltamab (REGN5458) was progressed as a clinical anti-multiple myeloma candidate. The EU EMA approved Linvoseltamab in April 2025, to treat multiple myeloma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05730036 A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma Phase 3 Interventional Regeneron Pharmaceuticals
External links Click here for help
For extended ADME data see the following:

European Medicines Agency (EMA)